Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Van Der Bruggen

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Cancer Immunology, Immunotherapy : CII|September 10, 2005
A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A24 carcinoma cellsSabrina Ottaviani, Didier Colau, Pierre van der Bruggen, et al.
Current Opinion in Immunology|March 14, 2003
T-cell responses of vaccinated cancer patientsPierre G Coulie, Pierre van der Bruggen
Current Opinion in Immunology|December 14, 2005
Processing and presentation of tumor antigens and vaccination strategiesPierre van der Bruggen, Benoît J Van den Eynde
Journal of Clinical Medicine|July 2, 2021
MDSC in Mice and Men: Mechanisms of Immunosuppression in CancerChristophe Vanhaver, Pierre van der Bruggen, Annika M Bruger
Oncoimmunology|August 7, 2014
Sugars boost exhausted tumor-infiltrating lymphocytes by counteracting immunosuppressive activities of galectinsMonica Gordon-Alonso, Nathalie Demotte, Pierre van der Bruggen
Blood|June 8, 2018
Extracellular galectins as controllers of cytokines in hematological cancerMonica Gordon-Alonso, Annika M Bruger, Pierre van der Bruggen
Cancer Immunology, Immunotherapy : CII|July 19, 2005
A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cellsSabrina Ottaviani, Yi Zhang, Thierry Boon, et al.
Cancers|November 12, 2013
Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccinesGrégoire Wieërs, Nathalie Demotte, Danièle Godelaine, et al.
Nature Communications|October 8, 2017
Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltrationMonica Gordon-Alonso, Thibault Hirsch, Claude Wildmann, et al.
Molecular Microbiology|July 26, 2002
YopH prevents monocyte chemoattractant protein 1 expression in macrophages and T-cell proliferation through inactivation of the phosphatidylinositol 3-kinase pathwayNathalie Sauvonnet, Isabelle Lambermont, Pierre van der Bruggen, et al.
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Cancer Immunology, Immunotherapy : CII|September 10, 2005
A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A24 carcinoma cellsSabrina Ottaviani, Didier Colau, Pierre van der Bruggen, et al.
Current Opinion in Immunology|March 14, 2003
T-cell responses of vaccinated cancer patientsPierre G Coulie, Pierre van der Bruggen
Current Opinion in Immunology|December 14, 2005
Processing and presentation of tumor antigens and vaccination strategiesPierre van der Bruggen, Benoît J Van den Eynde
Journal of Clinical Medicine|July 2, 2021
MDSC in Mice and Men: Mechanisms of Immunosuppression in CancerChristophe Vanhaver, Pierre van der Bruggen, Annika M Bruger
Oncoimmunology|August 7, 2014
Sugars boost exhausted tumor-infiltrating lymphocytes by counteracting immunosuppressive activities of galectinsMonica Gordon-Alonso, Nathalie Demotte, Pierre van der Bruggen
Blood|June 8, 2018
Extracellular galectins as controllers of cytokines in hematological cancerMonica Gordon-Alonso, Annika M Bruger, Pierre van der Bruggen
Cancer Immunology, Immunotherapy : CII|July 19, 2005
A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cellsSabrina Ottaviani, Yi Zhang, Thierry Boon, et al.
Cancers|November 12, 2013
Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccinesGrégoire Wieërs, Nathalie Demotte, Danièle Godelaine, et al.
Nature Communications|October 8, 2017
Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltrationMonica Gordon-Alonso, Thibault Hirsch, Claude Wildmann, et al.
Molecular Microbiology|July 26, 2002
YopH prevents monocyte chemoattractant protein 1 expression in macrophages and T-cell proliferation through inactivation of the phosphatidylinositol 3-kinase pathwayNathalie Sauvonnet, Isabelle Lambermont, Pierre van der Bruggen, et al.
Pageof 8